Eli Lilly Reports Phase 3 TRANSCEND-T2D-2 Results, With Retatrutide Achieving Greater A1C Reduction And Weight Loss Than Ozempic In Adults With Type 2 Diabetes

뉴스 본문을 불러오고 있어요.

Eli Lilly Reports Phase 3 TRANSCEND-T2D-2 Results, With Retatrutide Achieving Greater A1C Reduction And Weight Loss Than Ozempic In Adults With Type 2 Diabetes | 웨이프 WAPE

Eli Lilly Reports Phase 3 TRANSCEND-T2D-2 Results, With Retatrutide Achieving Greater A1C Reduction And Weight Loss Than Ozempic In Adults With Type 2 Diabetes

기사 요약

관련 종목

댓글 —